Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season

Background Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with certain health conditions. Adjuvanted RSVPreF3 and non-adjuvanted RSVpreF vaccines were approved in 2023 for use in adults aged ≥60 years in the United States (US). This s...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Frederik Verelst, David Singer, Jonathan Graham, Mei Grace, Elizabeth M. La, Eliana Biundo
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2025-12-01
Edice:	Expert Review of Vaccines
Témata:	Public health impact respiratory syncytial virus vaccination United States Markov model
On-line přístup:	https://www.tandfonline.com/doi/10.1080/14760584.2025.2539893
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!